deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 2-arm NCT02393625

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)

Sponsor: Novartis Pharmaceuticals

Conditions ALK-positive NSCLC
Interventions Ceritinib (LDK378) Nivolumab
Updated 26 times since 2017 Last updated: Jan 30, 2026 Started: May 27, 2015 Primary completion: Apr 9, 2027 Completion: Apr 9, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates ALK-positive NSCLC and is currently ongoing. Novartis Pharmaceuticals leads this study, which shows 26 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Oct 2020 · 8 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jun 2024 · 12 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 6 months · monthly snapshot

Change History

26 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Nov 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 21 earlier versions

  1. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Jun 2023 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  6. Sep 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE1

  7. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  8. May 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1

  9. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1

  10. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  11. Feb 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

  12. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  13. Aug 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  14. Mar 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  15. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  16. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  17. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  18. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  19. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  20. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE1

  21. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Boston, United States , Heidelberg, Australia , Hong Kong, Hong Kong , Leuven, Belgium , Milan, Italy , Modena, Italy , Philadelphia, United States , Scottsdale, United States , Singapore, Singapore and 1 more location